Get started
NeuroSense Therapeutics Ltd.NeuroSense Therapeutics Ltd.NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

NRSN chart


Full chart

NRSN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪29.60 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.70 USD
Net income (FY)
‪−11.28 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪13.48 M‬
Beta (1Y)
1.66

Employees


Employees (FY)
18
Change (1Y)
+4 +28.57%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−626.67 K‬ USD

About NeuroSense Therapeutics Ltd.


Sector
Health Technology
CEO
Alon Ben-Noon
Headquarters
Herzliya
Website
neurosense-tx.com
Founded
2017
ISIN
IL0011809592
FIGI
BBG0132WLB92
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NRSN news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of NRSN is 1.28 USD — it has increased by 2.40% in the past 24 hours. Watch NeuroSense Therapeutics Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NeuroSense Therapeutics Ltd. stocks are traded under the ticker NRSN.
NRSN stock has risen by 39.13% compared to the previous week, the month change is a 39.13% rise, over the last year NeuroSense Therapeutics Ltd. has showed a 58.83% increase.
We've gathered analysts' opinions on NeuroSense Therapeutics Ltd. future price: according to them, NRSN price has a max estimate of 3.00 USD and a min estimate of 3.00 USD. Watch NRSN chart and read a more detailed NeuroSense Therapeutics Ltd. stock forecast: see what analysts think of NeuroSense Therapeutics Ltd. and suggest that you do with its stocks.
NRSN reached its all-time high on Mar 21, 2022 with the price of 8.18 USD, and its all-time low was 0.40 USD and was reached on Oct 24, 2023. View more price dynamics on NRSN chart.
See other stocks reaching their highest and lowest prices.
NRSN stock is 9.80% volatile and has beta coefficient of 1.66. Track NeuroSense Therapeutics Ltd. stock price on the chart and check out the list of the most volatile stocks — is NeuroSense Therapeutics Ltd. there?
Today NeuroSense Therapeutics Ltd. has the market capitalization of ‪26.51 M‬, it has increased by 14.68% over the last week.
Yes, you can track NeuroSense Therapeutics Ltd. financials in yearly and quarterly reports right on TradingView.
NeuroSense Therapeutics Ltd. is going to release the next earnings report on Mar 19, 2025. Keep track of upcoming events with our Earnings Calendar.
NRSN earnings for the last quarter are −0.11 USD per share, whereas the estimation was −0.11 USD resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.08 USD per share. See more details about NeuroSense Therapeutics Ltd. earnings.
NRSN net income for the last quarter is ‪−2.15 M‬ USD, while the quarter before that showed ‪−857.00 K‬ USD of net income which accounts for −150.64% change. Track more NeuroSense Therapeutics Ltd. financial stats to get the full picture.
No, NRSN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 18.00 employees. See our rating of the largest employees — is NeuroSense Therapeutics Ltd. on this list?
Like other stocks, NRSN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NeuroSense Therapeutics Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NeuroSense Therapeutics Ltd. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NeuroSense Therapeutics Ltd. stock shows the buy signal. See more of NeuroSense Therapeutics Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.